Heart rhythm specialists awarded $3M to develop new AFib therapy

Cardialen, a Minnesota-based healthcare technology company, has received a $3 million grant from the National Institutes of Health to continue developing a new low-energy therapy for atrial fibrillation (AFib).

A panel of cardiologists, scientists and engineering specialists reviewed early data on Cardialen’s MultiPulse Therapy (MPT), which is designed to help patients who are already scheduled to receive an implantable cardiac resynchronization therapy defibrillator (CRT-D) device. AFib, the company noted, is quite common among patients with such devices.

Prash Sanders, MDDS, PhD, a cardiologist at Adelaide Medical School in Australia, led a clinical trial focused on MPT.

“AFib remains a serious arrhythmia, and additional treatment options are needed,” Sanders said in a prepared statement. “Maintaining AFib rhythm control in heart failure patients has shown to provide significant quality of life, mortality and hospitalization benefits. Cardialen’s MultiPulse Therapy could provide another important tool for patients receiving a CRT-D device.”

Michael Walter
Michael Walter, Managing Editor

Michael has more than 18 years of experience as a professional writer and editor. He has written at length about cardiology, radiology, artificial intelligence and other key healthcare topics.

Around the web

Ron Blankstein, MD, professor of radiology, Harvard Medical School, explains the use of artificial intelligence to detect heart disease in non-cardiac CT exams.

Eleven medical societies have signed on to a consensus statement aimed at standardizing imaging for suspected cardiovascular infections.

Kate Hanneman, MD, explains why many vendors and hospitals want to lower radiology's impact on the environment. "Taking steps to reduce the carbon footprint in healthcare isn’t just an opportunity," she said. "It’s also a responsibility."